Education
About Us
Working with TipRanks
Follow Us
Modern Healthcare Technology Holdings Limited (HK:0919)
:0919
RESEARCH TOOLSreports
Top Page
Modern Healthcare Technology Holdings Limited
(Frankfurt:0919)
Rating:56Neutral
Price Target:―
Modern Healthcare Technology Holdings Limited (0919) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
€76.88M
Dividend YieldN/A
Average Volume (3M)179.20K
Price to Earnings (P/E)26.6
Beta (1Y)-0.02
Revenue Growth19.26%
EPS GrowthN/A
CountryHK
Employees850
SectorConsumer Cyclical
Sector Strength70
IndustryPersonal Products & Services
Share Statistics
EPS (TTM)<0.01
Shares Outstanding904,483,950
10 Day Avg. Volume123,600
30 Day Avg. Volume179,200
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)0.40
Price to Sales (P/S)0.00
P/FCF Ratio1.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Modern Healthcare Technology Holdings Limited Business Overview & Revenue Model
Company DescriptionModern Healthcare Technology Holdings Limited, an investment holding company, provides beauty and wellness services in Hong Kong, the People's Republic of China, Singapore, and Australia. The company operates in two segments, Beauty and Wellness Services, and Skincare and Wellness Products. It offers beauty and facial services; aesthetics services, such as skincare treatment, professional consultation, skin care and anti-ageing, and referral services on plastic reconstruction; slimming services, including weight management programs; and spa and massage services comprising resplendent bathroom furnishings and a hydrotherapeutic pool, as well as foot spa, foot treatment, and foot massage services. The company also sells skincare and wellness products under the be, FERRECARE, p.e.n, Y.U.E., Advanced Natural, Malu Wilz, Byotea, Care Plus, Cellnoc, Mu-lan Spa, Cellnoc, Veribe, Castille, Dr Plus, Eclat du teint, and Natural Care brand names. In addition, it provides franchise and trademark services in relation to beautification and gymnastic services; advertising services; maid agency services; and management services, as well as food and beverage services. As of March 31, 2022, the company had 30 service centers in Hong Kong; 3 service centers in Mainland China; and 7 service centers in Singapore, as well as 8 be Beauty Shop outlets. Modern Healthcare Technology Holdings Limited is headquartered in Kowloon Bay, Hong Kong.
How the Company Makes MoneyThe company generates revenue through the sale of its medical equipment and technology solutions to healthcare providers and institutions. Key revenue streams include the direct sale of medical devices, recurring income from healthcare IT services, and maintenance and support contracts. Additionally, the company may engage in strategic partnerships with healthcare organizations and technology firms to expand its product offerings and market reach. These collaborations can lead to joint ventures or co-development projects, further contributing to the company's earnings. The company's focus on innovation and quality ensures a steady demand for its products and services in the competitive healthcare technology market.
Modern Healthcare Technology Holdings Limited Financial Statement Overview
Summary
The company shows revenue growth and a stable balance sheet but faces profitability issues with continuous net losses. While cash flow management is strong, the decline in free cash flow growth suggests a need for improved margin and profitability.Income Statement
The company's revenue has shown growth over the past year, increasing by 11.9% from 2023 to 2024. However, profitability is a concern as net income remains negative, reflecting a -2.1% net profit margin in 2024. Gross profit margin improved to 16.8%, but EBIT and EBITDA margins are low at 2.1% and 21% respectively, indicating operational challenges.45
Neutral
Balance Sheet
The company's balance sheet shows moderate leverage with a debt-to-equity ratio of 0.56, indicating manageable debt levels. The equity ratio of 31% implies a healthy equity base relative to total assets. However, return on equity is negative due to losses, which is a potential risk.60
Neutral
Cash Flow
Operating cash flow remains robust, though it has decreased compared to the previous year. Free cash flow also decreased by 48.9%, but the company maintains a positive free cash flow to net income ratio, signaling efficient cash management despite net losses. The operating cash flow to net income ratio is strong, suggesting effective cash conversion from operations.55
Neutral
| Breakdown | |||||
| TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 469.33M | 454.71M | 406.33M | 355.59M | 431.45M | 522.61M | Gross Profit |
| 128.49M | 166.96M | 394.72M | 341.52M | 417.67M | 503.69M | EBIT |
| 20.87M | 9.46M | -11.92M | -72.25M | 133.98M | -17.27M | EBITDA |
| 79.80M | 95.68M | 92.32M | 43.96M | 255.36M | 55.75M | Net Income Common Stockholders |
| 2.93M | -9.57M | -20.61M | -68.81M | 125.72M | -31.59M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 188.24M | 193.66M | 177.53M | 127.53M | 234.34M | 179.93M | Total Assets |
| 579.50M | 611.04M | 561.35M | 570.96M | 669.04M | 620.00M | Total Debt |
| 0.00 | 106.57M | 40.11M | 65.01M | 115.07M | 80.88M | Net Debt |
| -182.77M | -81.41M | -131.80M | -57.03M | -113.79M | -93.90M | Total Liabilities |
| 392.60M | 416.65M | 357.47M | 347.75M | 376.15M | 467.89M | Stockholders Equity |
| 181.25M | 189.33M | 199.77M | 219.58M | 289.37M | 146.79M |
| Cash Flow | Free Cash Flow | ||||
| 45.57M | 64.08M | 125.52M | -29.55M | 121.64M | 43.91M | Operating Cash Flow |
| 69.33M | 78.66M | 139.82M | 51.31M | 123.88M | 63.91M | Investing Cash Flow |
| -17.44M | 8.16M | -13.17M | -79.96M | -2.85M | -20.77M | Financing Cash Flow |
| -69.01M | -70.60M | -77.31M | -78.46M | -77.89M | -48.80M |
Modern Healthcare Technology Holdings Limited Technical Analysis
Positive
0.08
Price Trends
0.08
Positive
0.08
Positive
0.09
Negative
Market Momentum
<0.01
Positive
55.02
Neutral
77.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0919, the sentiment is Positive. The current price of 0.08 is below the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.08, and below the 200-day MA of 0.09, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 55.02 is Neutral, neither overbought nor oversold. The STOCH value of 77.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0919.
Modern Healthcare Technology Holdings Limited Peers Comparison
Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $6.94B | 11.29 | 2.95% | 3.87% | 2.70% | -24.49% | |
56 Neutral | €76.88M | 26.56 | 1.76% | ― | 19.26% | ― | |
| $10.21B | 42.06 | 6.14% | 1.34% | ― | ― | ||
| $11.48B | 16.93 | 13.20% | 4.42% | ― | ― | ||
| $8.66B | 12.84 | 6.22% | 1.96% | ― | ― | ||
| $6.00B | 18.55 | 14.19% | 1.23% | ― | ― | ||
| €3.63B | 8.18 | 3.10% | ― | ― |
* Consumer Cyclical Sector Average
Performance Comparison
HK:0919
Modern Healthcare Technology Holdings Limited
0.09
0.00
0.00%
SBMFF
Sino Biopharmaceutical
0.58
0.22
61.11%
CHJTF
CSPC Pharmaceutical Group
0.87
0.01
1.16%
SFOSF
Shanghai Fosun Pharmaceutical (Group) Co
1.96
0.20
11.36%
TRSBF
3SBio
2.22
1.41
174.07%
DE:640
China Resources Pharmaceutical Group Ltd.
0.57
-0.08
-12.31%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.